Licensing Technologies

Cell Cure Neurosciences Ltd., a subsidiary of BioTime, Inc., is a biotechnology company focused on developing cell therapies for retinal and neural degenerative diseases. Cell Cure technology is based on human embryonic stem cells (hESC), which, for the first time in the history of medicine, open the door to industrial-scale manufacture of any cell type in the human body. Cell Cure is using these powerful stem cells to manufacture a particular cell type in the retina called the Retinal Pigment Epithelial (RPE) cell.

Granalix Ltd. generates innovative formulations of natural compounds that increase their bioavailability and allow them to target organs of interest and, in particular, the brain. The company’s first product – GranaGard – is a submicron self-emulsion formulation of pomegranate seed oil (PSO). PSO contains high concentrations of Punicic Acid (PA), among the strongest natural antioxidants. GranaGard was shown to delay disease onset in a mouse model of genetic prion disease which presents neurodegenerative features reminiscent of Alzheimer’s disease and to reduce disease burden in a mouse model of Multiple Sclerosis.

Nobio develops, manufactures, and commercializes QASi, a novel, best-in-class antibacterial technology for medical and dental applications. Nobio has successfully developed and launched an antibacterial composite resin material called Infinix™, which incorporates the QASi particles. Infinix is a complete restorative system (including bonding agent and composites), and is the first FDA-cleared antimicrobial dental composite system with clinical claims of reducing demineralization, which is the critical part of the onset of the caries-formation process.

KAHR Medical Ltd. (“KAHR”) is an immuno-oncology drug development company whose mission is to develop novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. KAHR’s drug development pipeline is built around the Dual Signaling Proteins (DSP) technology which harnesses the power of the TNF Superfamily (regulators of the immune system) for treatment of disease. KAHR actively operates two drug-development programs, KAHR-101 and KAHR-102, representing proof-of-concept for its two proprietary platforms.

Moebius Medical Ltd. is a clinical stage biotechnology company which is developing a novel and sustainable pain relief treatment for osteoarthritis. The company’s lead product for osteoarthritis of the knee, MM-II, leverages the physical properties of proprietary liposomes to lubricate the joint and reduce friction and wear, thus leading to joint pain reduction.

GHF – Golden Heart Flower Ltd. was established to support people with glycogen storage diseases with limited treatment options. The company is developing a portfolio of oral medicines that target underlying disease pathogenesis. Based on the lead compound’s mechanism of action, larger commercial opportunities are being pursued. GHF was established by an entrepreneur who wanted to find a cure for his mother’s disease, and acquired the license from Or Kakhlon’s Laboratory of Experimental Neurology at Hadassah, in collaboration with Prof. Miguel Weil from Tel-Aviv University. Prof. Alexander Lossos opened the first clinical site at Hadassah Hospital.

Novel groundbreaking non-invasive guided intubation device, that enables clear identification of the trachea, as well as fast, accurate and safe intubations even in the most difficult clinical scenarios in which visualization of the trachea is very limited. The product is ISO 13485 certified and received the CE Mark and the FDA market approval.

Immuron Ltd. is a publicly-listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally-stable therapeutic as a potential oral targeted therapy for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, arthritis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in their pathogenesis.

Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Founded by leading patient organizations and biotechnology industry veterans, Akashi is managed by a seasoned team of drug development experts. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a fatal, aggressive muscle-wasting disease to a chronic, manageable condition.

Insuline Medical is a publicly-listed Israeli medical device company (INSL.TA). They developed a device that enables patients on intensive insulin therapy to take control of their disease and reach treatment targets in a more effective way. Insuline Medical has been active in developing a new approach to insulin therapy care since 2007, and has developed two medical devices using similar technology. InsuPatch & InsuPad are both designed to improve the current meal-time insulin therapy.

Inspired by the virtues of breast milk and its unique health properties, EXOSOMM is developing an exciting step towards care and quality of life for patients suffering from inflammatory bowel diseases (IBD). The company is backed by Prof. Shimon Reif, Head of the Department of Pediatrics at Hadassah, Dr. Regina Golan-Gerstl, Director of the Hadassah Pediatric Laboratory, and Dr.Yaffa Elbaum-Shiff, Deputy Director of the Department of Nutrition at Tel Aviv Medical Center, and led by CEO Netta Granot. Exosomm harnesses the natural properties of milk-derived nano-molecules found naturally in mammalian milk by creating a portfolio of exosomes-based nutritional solutions. The company was established in partnership with the Galil-Ofek incubator.

In October 2022 Hadasit in partnership with VLX Ventures has spun off a new cell therapy company called Sakura Bio. The company arises from the proprietary technology invented by Prof. Amnon Peled, Head of the Hadassah Gene Therapy Institute, and shall focus on developing SAK (super activated killer T cells). This is an off the shelf, allogenic T-cell therapy produced via a simple, relatively shot manipulation of naïve PBMC, applicable to a variety of cancers and particularly effective in acute myeloid leukemia (AML).

Immunyx is a drug development company focused on modulating neutrophil function to treat disease. Numerous high burden illnesses such as COPD, cancer, and arthritis involve deregulated neutrophils which exacerbate, and sometimes cause, the underlying pathology. Using its platform technology to specifically manipulate neutrophils using a targeted nanoparticle, Immunyx will bring new therapies to several diseases where neutrophil treatment could advance a cure. Currently there are no FDA approved drugs targeting neutrophil activity in disease, providing Immunyx the potential to provide first in class therapies for a variety of diseases. Immunyx was established in collaboration with VLX incubator, based on the development of Prof. Zvi Friedlander, Director of the Department of Internal Medicine and Corona at Hadassah Ein Kerem, Prof. Zvika Granot and Dr. Seth Salpeter from the Hebrew University.

BrainWatch Tech, established by the alumnies of the Jerusalem BioDesign program, is developing a real-time, continuous, automatic pupil reflex monitoring system. Our Solution is intended for assessing the neurological status of unconscious patients in cases of traumatic brain injury, stroke, and brain surgery.

NeuroGenesis is a clinical stage cellular therapy company focusing on a proprietary subpopulation of bone marrow stem cells that are selected and enhanced to become remyelinating & regenerative biofactory cells. The platform NG CELL™️ technology is optimized to treat central nervous system diseases such as progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

CardioVia provides the physicians with a minimally invasive access capability to the heart through the pericardium in order to treat the most prevalent Cardiovascular Diseases and arrhythmias without using a needle. ​By using cutting edge technologies with the simplest ideas CardioVia will facilitate performance of surgeries on the outer surface of the heart like never seen before.

Dio Tree is developing first-in-class small molecule for the treatment of ovarian cancer. The technology is based on inhibition of the enzyme DIO3, a major driver in many types of cancer, specifically, ovarian cancer. The molecule was developed by: Prof. Bernard Lerer, Founder of Hadassah’s Biological Psychiatry Laboratory and Hadassah BrainLabs;Dr. Tzuri Lifschytz of the Biological Psychiatry Laboratory; and Prof. Govindasamy Mugesh from the National Institute of Science in India. Prof. Lerer joined forces with Prof. Osnat Ashur-Fabian, Director of the Laboratory for Applied Oncology Research at the Hematology Institute at Meir Hospital, who led the preclinical study. This unique collaboration led to the establishment of DioTree.

EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy. The technology originates from collaboration between Dr. Sharon Merims, senior dermatologist and Head of the skin toxicity clinic at the Sharett Institute of Oncology at Hadassah Medical Center and Prof. Ofra Benny, an associate professor at the Institute for Drug Research in the School of Pharmacy at the Hebrew University.

Noxon is developing a groundbreaking drug to combat Idiopathic Pulmonary Fibrosis (IPF), a devastating disease characterized by lung fibrosis and limited survival. Through collaboration between Prof. Neville Berkman, Director of the Hadassah Department of Pulmonary Medicine and researchers from the Hebrew University of Jerusalem - Prof. Sara Goldstein and Prof. Amram Samuni,  a novel drug called 3-cabamoyl-proxyl (3-CP) has been discovered that holds immense potential to offer a safe and effective approach in the battle against IPF.